Julie S. Deutsch
A5068459053- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Polyomavirus and related diseases
- Cancer Research and Treatments
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- Bacteriophages and microbial interactions
- Bladder and Urothelial Cancer Treatments
- Cutaneous Melanoma Detection and Management
- Immune cells in cancer
- Nonmelanoma Skin Cancer Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- Meta-analysis and systematic reviews
- AI in cancer detection
- Scientific Computing and Data Management
- Biomedical Text Mining and Ontologies
Johns Hopkins Medicine
2023-2025
Johns Hopkins University
2022-2025
Sidney Kimmel Comprehensive Cancer Center
2023-2024
Bloomberg (United States)
2023-2024
University of Baltimore
2023
Abstract Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary (PT) lymph nodes (LNs)), is approved for treatment of resectable lung cancer. Pathologic assessment after neoadjuvant therapy the potential analog to radiographic advanced disease. However, %RVT thresholds beyond major (≤10% RVT) have not been explored. was prospectively assessed randomized, phase 3 CheckMate 816 trial...
PURPOSE Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because immunosuppression and risk treatment-related allograft loss (TRAL). We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers. METHODS Adult melanoma or basal, squamous, Merkel cell carcinomas were...
With a rapidly developing immunotherapeutic landscape for patients with metastatic clear cell renal carcinoma, biomarkers of efficacy are highly desirable to guide treatment strategy. Hematoxylin and eosin (H&E)-stained slides inexpensive widely available in pathology laboratories, including resource-poor settings. Here, H&E scoring tumor-infiltrating immune cells (TILplus) pre-treatment tumor specimens using light microscopy is associated improved overall survival (OS) three independent...
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses broad immune activation. We conducted a single-arm study of neoadjuvant agonist vidutolimod combined with nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR associated necrosis, melanophagocytosis increased CD8
Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab prior 15 evaluable with ccRCC. leveraged tissue from that cohort elucidate the effects PD-1 inhibition on immune populations ccRCC and correlate evolving milieu anti-PD-1 response. found durably induces pro-inflammatory state within primary tumor, baseline...
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional relationship between anti-tumor and anti-self immunity, facilitate irAE management while promoting immunity. Methods Multiple biopsies from tumor inflamed tissues were collected a patient melanoma experiencing both irAEs on ICB, who underwent...
<p>Figure S1</p>
<div>AbstractPurpose:<p>Co-mutations of the <i>Kirsten rat sarcoma virus</i> (<i>KRAS</i>) and <i>serine</i>/<i>threonine kinase 11</i> (<i>STK11</i>) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant chemoimmunotherapy is now a standard-of-care treatment for resectable NSCLC, clinical immunologic impacts <i>KRAS</i>...
<p>Figure S4</p>
<p>Figure S5</p>
<p>Figure S6</p>
<p>Figure S3</p>
<p>Figure S2</p>
Immunotherapy of cancer is now an essential pillar treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration new strategies incorporating agents in clinical practice. Immunotherapies perturb complex system interactions among genomically unstable cells, diverse cells within the microenvironment including systemic adaptive innate cells. The drive to develop increasingly effective immunotherapy regimens tempered by risk...
Systemic treatment options for patients with locally advanced or metastatic basal cell carcinoma (BCC) are limited, particularly when tumors refractory to anti-programmed death protein-1 (PD-1). A better understanding of immune checkpoint expression within the BCC tumor microenvironment may inform combinatorial strategies optimize response rates. CD3, PD-1, programmed ligand-1 (PD-L1), lymphocyte activation gene 3 (LAG-3), and T-cell immunoglobulin domain mucin (TIM-3)+ densities 34...
2515 Background: Immunotherapeutic agents are now being investigated for treating earlier-stage cancers. Radiographic assessment by RECIST, widely used to assess treatment response in clinical trials advanced cancers, has limitations the neoadjuvant setting; and pathologic is increasingly as a primary and/or secondary endpoint. To that end, pan-tumor scoring system assessing was developed (1,2). This allows quantitative of residual viable tumor (RVT) multiple locations: i.e. lymph node (LN)...
Intratumoral TLR9 agonists and anti-PD-1 therapies provide durable clinical responses broad immune activation. To evaluate the efficacy mechanisms of action this therapeutic combination, we conducted a single-arm phase 2 neoadjuvant study agonist vidutolimod combined with nivolumab in patients high-risk resectable melanoma. In 31 evaluable patients, 55% (17/31) had major pathologic response (MPR), eight grade 3 treatment-related adverse events. MPR was associated necrosis, melanophagocytosis...
<h3>Background</h3> Neoadjuvant PD-1 blockade combined with chemotherapy(ICB+chemo) is now standard of care for the treatment resectable non-small cell lung cancer(NSCLC).<sup>1–4</sup> However, mechanisms underpinning its therapeutic efficacy are largely unexplored, namely if chemotherapy has an immunomodulatory role when checkpoint agents(ICB).<sup>4–6</sup> We and others have shown that CXCL13 upregulated on tumor-reactive TIL. use as a surrogate tumor specificity to better understand...
Abstract Purpose: Co-mutations of the KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. While neoadjuvant chemoimmunotherapy is now a standard care treatment for resectable NSCLC, clinical immunologic impact andSTK11 co-mutations this setting unknown. Experimental design: We evaluated compared recurrence-free survival KRAS-mutated NSCLC tumors, or without co-occuring mutations, treated ICB. Single...